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The purpose of this study was to assess the hemodynamic
effects of intravenous digoxin in patients with New York
Heart Association class IV heart failure, who had never
previously been treated with digitalis drugs, and who
were initially treated only with dluretics and systemic
vasodilators to clinical end points of compensation. Eleven
male patients, 5 with idiopathic and 6 with ischemic
cardiomyopathy, had sinus rh ythm and were hospital-
ized with congesti ve heart failure not precipitated by an
acute ischemic event. All II patients were treated with
intravenous furosemide and var ious vasodilators without
invasive hemod ynamic monitoring for a mean period of
4.3 ± 2.1 days. This therapy resulted in subjective and
objective improvement in all pati ent s as reflected by a
significant decrease in heart failure score from 9.5 ±
2.2 to 2.7 ± 2.3 (p < 0.001 ).
When compensation was achi eved by clinical criteria,
the patients were instrumented and hemod ynamics ob-
ta ined before and serially thereaft er for 6 hours after
the intravenous administration of digoxin given in two
0.5 mg doses 2 hours apart. In response to digoxin ,
Although digitalis glycosides have been used in the treat-
ment of cardiac disorders for more than 200 years, contro-
versy persists regarding the relative role of these inotropic
agents in the treatment of patients with heart failure and
sinus rhythm. With the advent of more potent diuretics and
the demo nstrated benefit of vasodilators. the relati ve role
of digitalis glycos ides, as well as the new inotropic agents
under investigation in a multidru g approach to treatment of
heart failure, is being reexamined ( I ). In a previous study
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cardiac index increased from 2.6 ± 0.7 liters/min per
m2 to a peak of 3.3 ± 0.6 liters/min per m2 (p < 0.005);
left ventricular stroke work index (go m/m2) increased
from 27 ± 16 to 43 ± 23 (p < 0.005) and the ejection
fraction (eight patients) increased from 21 ± 13% to 29
± II % (p < 0.04). Mean pulmonary capillary wedge
pressure decreased from 24 ± 7 to a minimum of 17 ±
4 mm Hg (p < 0.02 ). Little hemod ynamic improvement
was observed after digoxin administration in 5 of the II
patients. Th ese five patients had a significantly lower
pulmonary capillary wedge pressure and higher cardiac
index before the administration of digoxin compared
with the six responders (p < 0.005 for both variables).
11 is concluded that although diuretics and systemic
vasodilators eliminated most of the clinical signs of heart
failure in all of the II pati ents in this study, adminis-
tration of intravenou s digoxin further improved cardiac
function in those patient s with persistence of abnormal
hemodynamic variables.
(J Am Coil Cardiol /987;9:849-57)
(2) , we showed that discontinuation of oral maintenanc e
digoxin therapy in patient s with compensated congestive
heart failure and sinus rhythm did not result in clin ical or
functional deterioration . At the time of digitalis discontin -
uation. these patients were receiv ing therapeutic doses of
diuretics and vasodilators.
Our study was undertaken to examine " the front end"
aspect of our previous study . We investigated the hemo-
dynamic effec ts of intravenous digox in in patients admitted
with severe heart failure who were first treated with diuretics
and vasodilators to clinical end points of compensation.
Methods
Study patients. Patients enrolled in this study wereamong
those admitted to the Salem Veteran 's Administration Med-
ical Center between December 1983 and December 1984
with a diagnosis of heart failure . Inclusion criteria were: I)
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stable sinus rhythm, 2) a history of chronic congestive heart
failure, and 3) clinical or radiographic pulmonary edema,
or both, at the time of admission to the hospital. Exclusion
criteria were: I) previous digoxin therapy, 2) myocardial
infarction or angina in the 3 months before the admission,
3) a cardiac ischemic event at the time of admission that
could have precipitated or worsened the heart failure, and
4) heart failure resulting from uncontrolled hypertension,
or valvular, pericardial, hypertrophic or restrictive heart
disease.
The study group comprised II consecutive men with
heart failure due to ischemic (6 patients) or idiopathic (5
patients) cardiomyopathy. Their ages ranged from 48 to 72
years (mean 52 years). The mean left ventricular ejection
fraction was 21 ± 13% (eight patients). All had an enlarged
cardiac silhouette on chest roentgenogram (cardiothoracic
ratio >0.55). Before admission each patient had New York
Heart Association class IV heart failure symptoms ranging
in duration from 15 to 45 days.
Prestudy clinical features. Each patient was assigned
a heart failure score on the basis of symptoms, clinical signs
and findings on chest roentgenogram. For scoring purposes,
each of the following signs and symptoms was assigned one
point: I) dyspnea on exertion; 2) orthopnea; 3) dyspnea at
rest; 4) tachypnea (respiratory rate >20/min); 5) sinus tachy-
cardia (heart rate> 110 beats/min); 6) jugular venous dis-
tension (>6 em water); 7) jugular venous distension and
ankle edema or hepatomegaly, or both; 8) pulmonary rales;
9) S3 gallop; 10) cardiothoracic ratio >0.55; II) interstitial
edema; 12) alveolar edema; and 13) pleural effusion. The
assigned scores ranged from 0, which reflected an absence
of the 13 variables listed above, to a maximal score of 13,
representing the presence of each of the listed findings.
Each patient was treated initially with intravenous fur-
osemide and various vasodilators administered without in-
vasive monitoring (Table I). The duration of therapy ranged
from 2 tei 6 days with a mean of 4.3 days. Before therapy
all patients had overt heart failure with a mean heart failure
score of 9.5 ± 2.2. Intravenous diuretics and vasodilators
rendered all patients asymptomatic in the hospital, as re-
flected by a significant decrease in heart failure score to a
mean of 2.7 ± 2.3 (Fig. 1) (p < 0.001). Once a plateau
in improvement of the heart failure score was achieved, the
patients were considered to be at baseline status. All had
normal serum electrolytes and stable sinus rhythm.
Study protocol. After informed written consent was ob-
tained, on the same day before hemodynamic investigation,
a serum digoxin level was obtained (by radioimmunoassay
Table 1. In-Hospital Therapy Before Digoxin Administration in 11 Patients
Intravenous
Cause Furosemide
Patient of Heart Age Dose (mg)
No. Failure (yr) Per Day Vasodilator (dose)
CAD 58 120 Prazosin (12 rug/day).
isosorbide dinitrate (40
mg/day)
2 CAD 72 80 Sodium nitroprusside (1.5
JoLg/kg per min)
3 DCM 57 80 Captopril (150 mg/day)
4 CAD 48 40 Nifedipine (30 mg/day),
isosorbide dinitrate (80
mg/day)
5 DCM 63 80 Isosorbide dinitrate (160
mg/day)
6 DCM 70 160 Sodium nitroprusside (1.5
JoLg/kg per min)
7 DCM 50 80 Prazosin (6 mg/day),
isosorbide dinitrate (160
mg/day)
8 CAD 59 80 Prazosin (3 rug/day).
sodium nitroprusside
(0.75 JoLg/kg per min)
9 DCM 56 80 Prazosin (6 rug/day)
10 CAD 68 80 Nifedipine (60 mg/day),
isosorbide dinitrate (80
rug/day)
II CAD 50 80 Isosorbide dinitrate (160
rug/day)
CAD = coronary artery disease; DCM = dilated cardiomyopathy.
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Figure 1. Heart failure score in II patients before and after the
administration of intravenous furosemide and various vasodilators
for a mean of 4.3 days.
method) and radionuclide left ventricular ejection fraction
was determined by a method previously described (2) .
Hemodynamic studies were performed in the morning with
all patients in the postabsorptive state. Diuretics and vaso-
dilators were withheld the morning of the study. During the
study period patients remained in a fasting state and were
not given any hemodynamically active drugs. with the ex-
ception of three patients who received a constant infusion
of sodium nitroprusside beginning at least 12 hours before
the study. Before digoxin administration, a balloon-tipped
triple-lumen thermodilution catheter was advanced to the
pulmonary artery and a short plastic catheter was inserted
percutaneously into the radial artery. The procedure was
conducted in a quiet private room. Heart rate, cardiac output
and systemic arterial, pulmonary arterial, pulmonary cap-
illary wedge and right atrial pressures were determined in
all patients. To document stability of the control hemody-
namic data, measurements were repeated at 30 minute in-
tervals until there was < 10% variability in cardiac output
and pulmonary capillary wedge pressure. Systemic arterial
and right-sided cardiac pressures were obtained using an
HP-1290C pressure transducer calibrated against mercury,
and were recorded on a multichannel physiologic recorder.
The reference for determination of all pressures was a plane
in the midaxillary line at the level of the sternal angle.
Measurements. Cardiac output was determined by the
thermodilution technique using an Edwards Laboratory
computer (model 9520A) and 10ml injectionof 5% dextrose
in water at 0 to 4°C. Each value represented an average of
Serum digoxin concentration. This concentration was
below the limits of the assay in all patients during the control
period. Six hours after the infusion of the second dose of
digoxin. the serum digoxin level ranged from I to 2.7 ng/rnl
with a mean level of 1.7 ng/rnl,
Hemodynamic findings. The central hemodynamics
profile of individual patients is presented in Table 2. The
peak hemodynamic effect of digoxin was observed between
I and 3 hours after the infusion of the second dose of digoxin
(mean = 1.9 hours). Intravenous administration of 1 mg
digoxin increased the mean cardiac index by 30% from 2.6
± 0.7 to a peak of 3.3 ± 0.6 liters/min per m' (p <0.005).
The mean stroke work index was augmented by 62% from
27 ± 16 to 43 ± 23 gm/nr' (p < 0.005). The mean
Results
three consecutive injections. Hemodynamic variables were
calculated on-line by a computer as follows: cardiac index
(liters/min per rrr' ) = cardiac output (liters/min) divided by
body surface area (rrr ' ). Stroke volume index (rnl/rrr' ) =
cardiac index divided by heart rate. Mean arterial pressure
(rn rn Hg) = 1/ 1 (systolic - diastolic pressure) + diastolic
pressure. Left ventricular systolic mean pressure = 2/, (sys-
tolic - diastolic mean pressure) + diastolic pressure. Left
ventricular stroke work index (g -rn/nr') = stroke volume
index (left ventricular systolic mean pressure - mean pul-
monary capillary wedge pressure) x 0.0136. Total systemic
vascular resistance (dynes-s-cm 5) = (mean arterial pres-
sure - right atrial pressure) X gO divided by cardiac output.
Digoxin administration . After the baseline hemody-
namic measurements had been obtained, each patient re-
ceived 0.5 mg digoxin in 50 ml of 5% dextrose in water
infused intravenously over a 15 minute period. The rate of
infusion was chosen to avoid the undesirable vasoconstric-
tion that digoxin has been shown to induce when admin-
istered rapidly (3- 5). A second dose of 0.5 mg digoxin was
given in the same manner 2 hours later. After the first dose
of digoxin, hemodynamic measurements were obtained at
60 minute intervals over a 6 hour period. The electrocar-
diogram (ECG) was monitored continuously and hourly
computation of the number of premature ventricular com-
plexes was obtained by a computerized arrhythmia detection
and recall system.
The radionuclide ejectionjraction and the serum digoxin
level were measured 6 hours after completion of the infusion
of the second dose of digoxin.
Statistical analysis . Values were expressed as mean and
standard deviation. Changes in hemodynamic variableswere
evaluated using the paired t test. Comparison between groups
was performedusing analysis of variance. Values were con-
sidered statistically significant iI' the probability (p) value
was < 0.05.
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Table 2 . Effects o f D igo xin o n Cen tra l Hemodyn amic Measurement s in II Patients zZ
Time (hou rs) T ime (hours) ."
Patient >
-I
No. c * I 2* 3 4 5 6 c * I 2* 3 4 5 6 tr.z
-I
'"
HR (beals/min) AP (rnrn Hg) ~
=1
:r:
I 11 5 115 119 113 116 114 113 106 11 3 110 107 106 90 90 :r:
2 102 100 110 97 98 100 70 80 87 90 90 95 m- - >
82 76 78 86 73 74 130 140 142
;;c
3 83 105 130 140 146 -I
4 85 74 71 69 74 74 82 75 81 85 81 82 XO X9 "T1>
5 95 91 9 1 92 100 92 92 11 4 98 103 100 99 94 100 rC
6 100 96 101 105 96 96 94 '11,7 95 104 104 96 97 105 ;;c(TO
7 97 88 85 76 83 77 77 120 120 11 7 11 7 123 120 123
8 I I I 109 105 105 103 107 102 '11,3 81 80 82 8 1 87 'J2
9 100 96 101 95 101 106 96 90 97 93 100 100 117 92
10 84 81 113 70 84 90 84 104 lOll 97 97 103 100 !O3
II 100 107 80 80 80 80 110 96 87 85 115 86 X2 30
Mean 97 94 92 89 92 9 1 89 95 99 99 100 101 97 102
±SD ± 12.0 ± 12.7 ± 15.3 ± 15.3 ± 12.4 ::':: 14 .3 ::':: 12.2 ::':: 16.0 ::':: 16.9 ± 15.4 ± 17.2 ± 18.4 ::':: 17.8 ::':: 19.5
P Value NS NS < 0.01 NS NS < 0.0 1 NS NS NS NS NS NS
PCWP (rnrn Hg) RAP (rnm Hg)
I 28 25 24 20 20 20 21 X 5 6 7 4 5 5
2 23 23 18 IX 18 19 - 9 4 2 6 5 5
3 18 15 16 16 18 18 19 6 8 3 8 9 7 8
4 35 26 26 25 18 20 20 5 4 3 5 2 5 4
5 30 25 26 27 22 20 21 6 4 5 6 4 4 4
6 21 22 22 20 22 22 21 10 12 13 I I 19 19 16
7 30 22 20 18 20 15 16 10 8 8 7 10 6 7
8 20 19 18 17 18 IX 17 6 4 5 3 0 2 2
9 18 22 22 23 22 22 22 4 5 3 2 4 5 6 »
10 9 7 8 8 7 7 10 4 2 3 2 I 0 3 "On::!.n
II 22 20 20 15 17 18 17 15 15 8 8 8 10 10 =<
-a C
00 .
Mean 24 21 20 19 18 18 18 8 7 6 6 6 6 7 :--:J -.coc •
±SD ± 7.3 ± 5.5 ±5 .1 ± 5.2 ± 4.2 ± 4.2 ±3 .6 ± 3.3 ± 4.0 ± 3.3 ± 2.8 ± 5A ± 5.0 ± 4. 1 <-z!~
p Value <0.05 < 0.03 < 0.02 < 0.03 < 0.03 < 0.05 NS NS NS NS NS NS ....,<-
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Table 2. (continued)
Patient
Time (hours) Time (hours)
No. C* I 2* 3 4 5 6 C* I 2* 3 4
CI (liters/min per m') TSVR (dynes-s-cm 5)
I 2.3 3.4 3.2 3.1 3.2 28 2.9 1848 1528 1402 1374 1383
2 2.1 3.1 2.8 3.0 3.0 3.0 1338 1132 1417 1306 1340
3 3.7 3.8 3.4 3.7 3.8 3.9 4.0 1117 1341 1495 1486 1462
4 2.1 2.5 2.5 2.6 2.5 2.7 2.7 1560 1442 1510 1320 1480
5 2.1 2.1 2.1 2.4 2.6 2.4 2.4 2101 1829 1921 1637 1496
6 3.7 3.5 3.6 3.6 3.4 3.5 3.9 948 1053 1139 1141 1021
7 2.5 3.2 33 3.1 3.2 41 4.0 1725 1376 1283 1396 1392
8 2.7 3.1 2.5 2.7 2.7 2.7 2.5 1397 1226 1487 1472 1481
9 2.4 2.4 2.3 2.9 3.0 2.6 2.2 1704 1795 1813 1570 1517
10 3.2 3.9 4.1 4.7 3.8 4.0 4.5 1292 1135 961 842 1121
II 1.6 2.3 2.8 3.4 3.3 3.2 2.5 1807 1138 1018 ~U5 877
Mean 2.6 3.0 3.0 3.2 3.1 32 3.1 1531 1364 1405 1308 1325
±SD ±068 ±0.61 ±061 ±0.65 ±0.44 ±0.6J ±0.84 ±346 ±266 ±298 ±268 ±218
p Value <0.004 <0.04 <0.006 <0.005 <0.007 <0.02 NS NS NS NS
LVEF (C;')
LVSWllg·m/m') C D
21 31 31 32 31 23 23 16 23
2 13 24 23 30 29 30
3 53 71 69 79 75 88 91 43 52
4 13 24 28 28 29 29 30 23 26
5 25 23 24 25 27 26 28 19 23
6 32 36 39 39 36 37 47
7 31 48 51 54 53 76 75 28 38
8 21 23 19 22 22 23 24 9 II
9 23 25 22 32 31 21 21
10 50 66 59 81 59 55 66 32 27
II 17 19 30 39 38 34 26 13 28
Mean 27 36 36 42 40 41 44 21 29
±SD ±16 ±18 ±17 ±21 ± 16 ±23 ±25 ± 13 ±II
p Value <0.003 <0.003 <0.008 <0.007 <0.02 <0.02 <0.04
"Digoxin 0.5 mg was administered at the end of the control period and at 2 hours. AP = mean systemic arterial blood pressure: C = control:
CI = cardiac index: D = obtained at 6 hours after the second dose of digoxin: HR = heart rate: LVEF = left ventricular ejection fraction: LVSWI = left ventricular
stroke work index: NS = not significant at the :s0.05 level: p = probability of difference compared with control: PCWP = mean pulmonary capillary wedge pressure:
RAP = mean right atrial pressure: TSVR = total systemic vascular resistance.
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Table 3. Peak Hemodynamic Response to Digoxin in II Patients
HR (hea ts/min)
A P (rnm Hg)
PCWP (rnm Hg)
RAP (rnrn Hg)
CI (li ters/min per m' )
TSVR (dynes-s-cm ' )
LVSW I (g-m/m")
EF ( ~k) (n = 8)
Co ntrol
107 :!:: 24
97 :!:: 21
2S ± 5
9 ± 3
2.1 :!: 0.3
1.775 :!: 317
19 ± 8
20 ± 6
Responders (n = 6)
Digoxin
98 :!:: 29
96 :!:: 14
18 :!:: 2
5 :!:: 2
3. 1 :!:: 0 .02
1.229 ± 236
37 :!:: 20
28 ± 6
Nonrespo nders (n = 5)
P Value Control Digoxin p Value
< 0 .05 85 :!:: 12 85 :!:: 13 NS
NS 94 :!:: 10 106 :!: 24 NS
< 0 .004 17 ± 5 17 :!: 6 NS
< 0.003 6.0 ± 2 5.0 ± 5 NS
< 0.02 3. 1 :!:: 0 .6 3.4 ± 0 .6 NS
< 0 .04 1.285 ± 282 1.332 :!: 2 1S NS
< 0 .03 36 ± 15 50 :!: 27 NS
< 0.03 2S ± 17 30 :!: 20 NS
EF = ejection fraction: other abbreviatio ns as in Table 2.
pulmonary capillary wedge pre ssure decreased from 24 ±
7 to 17 ± 4 mm Hg (p < 0 .02) . No significant changes
were obse rved in mean aortic pressure and systemic vascular
resistance after the administrati on of digoxin. There was a
trend for the right atrial pressur e and systemic vascular
resistance to decrease in most of the patient s. Gated blood
pool sc intigraphy performed in eig ht patient s before and
after the administration of intravenou s digoxin demonstrated
a significant increase in the mean left ventricular ejection
fract ion from 21 ± 13 to 29 ± 11 % (p < 0 .04) .
Development of arrhythmias. Except for one pat ient
(Patient 2) who developed multi focal atrial tachycardia 5
hours after the first dose of digoxin , there were no significant
changes in the hourl y frequ ency of atrial or ventricular pre-
mature depolarizations during the follow-up period.
Responders versus nonresponders. Although all pa-
tient s had a decrease in pulmonary capillary wedge pre ssure
or an increase in cardiac index in response to intravenous
digoxin , a significant hemodynami c effect was not observed
in all patients . On the basis of the respon se of the pulmonary
capillary wedge pressure and cardi ac index to the digoxin,
patients were placed in two ca tego ries: responders and non-
responders . Because minor beneficial hemod ynamic change s
ca n occu r spontaneously with time (6 ), we arbitrarily defined
the responders as patient s who demonstrat ed a decrease in
pulmonary capillary wedge pressure of > 5 mrn Hg and an
incre ase in cardiac index of > 0 .5 liters/min per nr' after
digoxin administration. By this arbitrary separation. six pa-
tient s responded to digo xin and five did not. In the nonre-
sponder group (Table 3), no significant changes in heart rate ,
mea n sys temic blood pressure , pulmo nary capillary wedge
pressure. right atrial pressure, card iac index, total sys temic
vasc ular resistan ce, stroke work index and left vent ricul ar
ejectio n frac tion we re noted afte r digoxin administration.
In this group (although stati stically insignificant probably
because of a small sample size) there was a trend toward
an increa se in cardiac index and stroke work inde x desp ite
an increase in total systemic vasc ular resistance .
In co ntrast , a significant incre ase in cardiac index, strok e
work index , left ventricular eject ion fraction and a signifi-
cant decrease in heart rate , pulmonary capillary wedge pres-
sure , right atrial pressure and total systemic vascular re-
sistance were observed in the six responders (Table 3) .
Although age, cause of heart failure, magnitude of the heart
failure score and duration of therapy we re similar in the two
gro ups. a marked difference between responders and non-
responders was found in rest hem odynamics before admin-
istra tion of digoxin (Fig . 2). Before digoxin administration ,
nonresponders had a significantly lower pulmonary capillary
wedge pressure ( 17 versus 28 mm Hg: p < 0 .005 ) and a
higher cardi ac inde x (3 .1 versus 2. 1 liters/min per rrr' ; p <
0 .005) when compared with the responders. After prior
treatment with diuretics and vasodil ators , two patients in
the respond er group had an abnormally high serum creati-
nine and urea nitro gen , one patient had a sys tolic pressure
of 90 mm Hg and no jugular venous distension and the
remaining three pat ient s had orthostatic hypotension .
Discussion
Our findings demonstrate that diuretic and vasodilator
therapy alone was effective in e liminating signs and symp-
toms of heart failure in a cohort of 11 patients admitted with
New York Heart Association class IV heart failure . Thi s
Figure 2. Baseline differences in cardiac index and pulmonary
capillary wedge pressure (PCWP) between five nonresponders and
six responders. immediately before the administration of digoxin.
4 ~P<O.OO5-, 30
r: 253 20CARDIACINDEX 2 15 PCWP"~.::I:&n mm Hg
~ 10 0
5
0 0
NON- RESPONDERS
RESPONDERS
n=5 n = 6
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was reflected by a significant diminution in the heart failure
score, on the basis of clinical symptoms and signs and
radiographic manifestations of heart failure. Despite this
marked clinical improvement for the group as a whole,
approximately one-half of the patients had persistently ab-
normal rest hemodynamic variables after receiving maximal
or near maximally tolerable doses of diuretics and vasodi-
lators. Other investigators (7-9) have also found no good
correlation between signs, symptoms and exercise capacity
and hemodynamic variables at rest in patients with heart
failure. In our patients, all of whom appeared clinically
compensated after diuretic and vasodilator therapy, admin-
istration of I mg of intravenous digoxin in two divided doses
given 2 hours apart resulted in a significant increase in mean
cardiac index, left ventricular stroke index and ejection frac-
tion, and a decrease in pulmonary capillary wedge pressure.
By predetermined criteria, we ascertained that there were
six "responders" to intravenous digoxin in this group of
II patients. It is possible that in these six patients, prior
therapy was not really maximal and higher doses of diuretics
Or vasodilators, or both, might have resulted in further im-
provement of rest hemodynamics, However, this hypothesis
is unlikely because among the six responders, two developed
azotemia while being treated with diuretics and vasodilators,
one had a systolic blood pressure of 90 mm Hg and three
had orthostatic hypotension, These observations suggest that
maximal or near maximal doses of diuretics and vasodilators
had been employed before digoxin administration.
Digitalis and systemic vascular resistance. Failure to
respond to digoxin with hemodynamic improvement may
be related to changes in systemic vascular resistance. Dig-
italis glycosides increase total systemic vascular resistance
in normal subjects (3) and constrict arterioles in the coronary
(10), skeletal muscle (II), renal (12) and possibly mesen-
teric beds (13). In contrast to the vasoconstrictive action
uniformly observed in the normal circulation, the reported
effects of digitalis on total systemic vascular resistance in
patients with chronic heart failure have been variable. The
widely held view (14) that digitalis reduces peripheral re-
sistance in cardiac failure by improving cardiac perform-
ance, thereby relieving reflex vasoconstriction, has not been
shown to be consistently valid (15,16). Mason and Braun-
wald (14) studied the effects of intravenous ouabain in six
patients not receiving medical therapy who had severe heart
failure and markedly abnormal central hemodynamic vari-
ables. All had a significant increase in cardiac output and
a significant decrease in forearm vascular resistance and
forearm venous tone in response to ouabain.
In patients with a lesser degree of heart failure or in those
whose hemodynamic variables were first improved by di-
uretic therapy, the systemic vascular resistance remained
unchanged (15) or was actually augmented by digitalis
administration (16). In Ribner's series (15), digoxin (given
intravenously to a group of men with heart failure secondary
to alcoholic or idiopathic cardiomyopathy, in whom all drugs
being employed for heart failure treatment were discontin-
ued 2 days before study) caused an increase in cardiac index
and a decrease in pulmonary capillary wedge pressure at
rest and during exercise without change in systemic vascular
resistance. Cohn et al. (16) administered digoxin to eight
patients with compensated heart failure on maintenance di-
uretic therapy, Digoxin caused hemodynamic deterioration
in four patients that coincided with an increase in total
systemic vascular resistance, Of interest is that the four
patients whose condition deteriorated had a significantly
higher cardiac output and a lower pulmonary capillary wedge
pressure before digoxin administration when compared with
the other four who were responders,
In our study none of the nonresponders actually showed
worsening of heart failure with oligoxin administration as
reported by Cohn et al. (16). This is most likely because
the prior treatment with vasodilator therapy prevented an
acute increase in systemic vascular resistance in response
to the drug. In addition, in our study intravenous digoxin
was administered slowly, which probably attenuated any
acute peripheral vasoconstrictor effect.
Thus, the increased myocardial contractility produced by
digoxin may not always be translated into a significant in-
crease in cardiac output or a reduction in filling pressure.
This may be due to a concomitant increase in total systemic
vascular resistance from direct actions of digitalis on pe-
ripheral arterioles that increase the afterload stress on the
left ventricle. Clinical improvement in symptoms and signs
of heart failure is usually related to an increase in cardiac
output and a decrease in pulmonary capillary wedge pres-
sure, and not to an increase in cardiac contractility alone.
Comparison with previous studies. Results of our study
are in general agreement with those of others (17-21) who
found an overall improvement in hemodynamic variables
when digitalis was administered intravenously in patients
with heart failure despite the presence of a subgroup of
nonresponders. In contrast to our study, some prior studies
have included patients with valvular heart disease, severe
hypertension, atrial fibrillation and no clinical evidence of
heart failure. In some studies, intravenous digoxin was ad-
ministered rapidly, neglecting to consider the vasoconstric-
tor effect of this drug. Moreover, most observations on the
effects of digoxin in prior studies were usually made for
periods no longer than 2 hours after digoxin administration.
Finally, there are scant data concerning the relative bene-
ficial effects of digoxin when compensation of heart failure
was first achieved with diuretic and vasodilator therapy.
There are some significant similarities between our re-
sults and those reported previously. Selzer and Malmborg
(22) showed that 5 of 15 patients receiving digoxin for heart
failure and sinus rhythm did not respond to the drug. As in
our study, these investigators found that responders had a
lower cardiac output and higher pulmonary artery diastolic
pressure before drug administration. Yankopoulos et al. (23)
reported that only class III and IV patients had a significant
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increase in cardiac index and a significant decrease in left
ventricular end-diastolic pressure in response to intravenous
ouabain. Our data show that patients with persistence of
abnormal rest hemodynamic variables are more likely to
respond to intravenous digitalization, with an improvement
in cardiac output and a decrease in filling pressure, regard-
less of clinical status. Data from both our study and prior
studies are consistent with the hypothesis that patients with
severe heart failure may exhibit maximal vasoconstriction
and therefore when digoxin is administered, further vaso-
constriction does not occur, permitting the positive inotropic
effect of the drug to be translated into an increase in cardiac
output and decrease in pulmonary capillary wedge pressure.
In patients whose hemodynamic variables improved signif-
icantly with non inotropic therapy and whose systemic vas-
cular resistance has been reduced to the normal range, in-
travenous digoxin could augment afterload, thereby preventing
a significant increase in cardiac output.
Long-term maintenance digoxin therapy in patients
with heart failure and sinus rhythm. We previously re-
potted (2) that in patients with coronary ischemic heart
disease and compensated congestive heart failure with sinus
rhythm, digoxin withdrawal had no adverse clinical or
hemodynamic effects when diuretic or vasodilator therapy,
or both, was first maximized. Although both the prior studies
and our present studies examine the effects of digoxin in
heart failure patients already receiving maximal or nearly
maximal diuretic and vasodilator drug therapy, our previous
study examined only the long-term and not the short-term
effects of the drug. Despite these differences, both studies
clearly show that patients with heart failure who are com-
pensated hemodynamically or clinically, or both, with di-
uretics and vasodilators do not benefit from digoxin therapy.
In our present study the six responders differed from the
patients on whom we previously reported in that the re-
sponders had more severe heart failure manifested by a
higher heart failure score, greater incidence of an S, gallop
and lower left ventricular ejection fractions.
We cannot predict if the hemodynamic benefit observed
in the six digoxin responders in this short-term study would
have been sustained with long-term oral maintenance dig-
oxin therapy because long-term follow-up observations were
not undertaken. It is possible, however, that long-term dig-
oxin therapy might have shown a sustained benefit in these
patients whose hemodynamic variables remained abnormal
after diuretic and vasodilator therapy. This prediction is
supported by data from other studies that have correlated
short- and long-term effects of digoxin in patients with sinus
rhythm with heart failure with differing degrees of com-
pensation. Arnold et al. (24) studied nine patients on long-
term digoxin therapy, after withdrawal of the drug and 5
hours after readministration. All nine patients had deterio-
ration of left ventricular function after digoxin withdrawal.
Interestingly, all had an S3 gallop and a very high pulmonary
capillary wedge pressure (33 ± 7 mm Hg) before digoxin
withdrawal. Thus, all were "uncompensated" at the time
of digoxin administration.
Lee et al. (25) reported a benefit of oral digoxin in com-
parison with placebo in 56% of patients with chronic heart
failure. Only patients with severe heart failure and an S3
gallop responded clinically to digoxin. In contrast, in two
studies (26,27) that examined the role of long-term digoxin
therapy in patients with well compensated heart failure re-
flected by a low "heart failure score," absence of an $3
gallop or only modest hemodynamic abnormalities, little or
no benefit from oral digoxin was observed. The results of
our two studies confirm these observations.
Clinical implications. Because both digitalis and the
newer inotropic agents currently undergoing clinical trials
show a narrow therapeutic-toxic tatio or substantial non-
cardiac side effects, it would seem prudent to first treat all
patients with heart failure with maximally tolerated doses
of diuretics and vasodilators. Then, only if clinical evidence
of decompensation (for example, $3 gallop, jugular venous
distension, pulmonary rales) persists, or if abnormal hemo-
dynamic variables (for example, depressed cardiac index,
elevated pulmonary capillary wedge pressure or elevated
systemic vascular resistance) are present, should digoxin or
a newer inotropic agent be added to the therapeutic regimen.
This may not hold true for the phosphodiesterase inhibitor
class of inotropic agents (that is, amrinone and milrinone)
because these drugs have significant vasodilator properties
in addition to their inotropic effects. On the other hand, the
significant increase in myocardial oxygen demand resulting
from potent inotropic stimulation of the myocardium may
be deleterious in situations in which concomitant enhance-
ment of nutrient myocardial blood flow does not occur.
Conclusion. Our data suggest that diuretic and vasodi-
lator therapy administered without hemodynamic monitor-
ing was effective in eliminating most of the clinical and
radiographic signs of heart failure in all II patients with
severe congestive heart failure included in this study. Sub-
sequent intravenous digoxin administration achieved hemo-
dynamic improvement only in the 6 patients with persistence
of abnormal rest hemodynamic variables. Further clinical
studies appear warranted to determine whether this acute
beneficial effect is sustained.
We express our appreciation to Elaine Busz for secretarial assistance in
the preparation of this paper.
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